Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIZMYQ)

• Drug Name: Roxatidine Drug Info
• Synonyms: Desacetyl-tzu-0460; IV9VHT3YUM; ROXATIDINE; Roxatidine (INN); Roxatidine [INN:BAN]; 2-hydroxy-N-(3-(3-(piperidin-1-ylmethyl)phenoxy)propyl)acetamide; 2-hydroxy-N-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]acetamide; 2-hydroxy-n-{3-[3-(piperidin-1-ylmethyl)phenoxy]propyl}acetamide; 78273-80-0; 97900-88-4; Acetamide, 2-hydroxy-N-(3-(3-(1-piperidinylmethyl)phenoxy)propyl)-; C17H26N2O3; N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]hydroxyacetamide; N-{3-[3-(1-Piperidinylmethyl)phenoxy]propyl}hydroxyacetamide; UNII-IV9VHT3YUM
• Cross-matching ID:
  PubChem CID: 91276
  CAS Number: CAS 78273-80-0
  TTD Drug ID: DMIZMYQ
  INTEDE Drug ID: DR1447

Molecule-Related Drug Atlas

Drug(s) Metabolized By Cytochrome P450 2A6 (CYP2A6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[2]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[3]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[4]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[5]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[3]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[6]
Metronidazole	DMTIVEN	Abscess		Approved	[7]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[8]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[9]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[3]

Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[10]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[11]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[12]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[5]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[13]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[14]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[15]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[16]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[17]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[18]

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[1]
Cytochrome P450 2A6 (CYP2A6)	DEJVYAZ	CP2A6_HUMAN	Substrate	[1]

References

• [1] Cytochrome P450 enzymes involved in the metabolic pathway of the histamine 2 (H2)-receptor antagonist roxatidine acetate by human liver microsomes. Arzneimittelforschung. 2001;51(8):651-8.
• [2] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [3] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [4] Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
• [5] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [6] Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
• [7] The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
• [8] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [9] CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.
• [10] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [11] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [12] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [13] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [14] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [15] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [16] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [17] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [18] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.